Skip to content

Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study

Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study, the Kitanagoya Genome (KING) Study for the Local Residents of Kitanagoya, Japan

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00262691
Enrollment
7000
Registered
2005-12-07
Start date
2005-05-31
Completion date
Unknown
Last updated
2007-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Infarction, Coronary Disease, Healthy, Myocardial Infarction

Brief summary

Cardiovascular disease is a complex multifactorial and polygenic disorder that is thought to result from an interaction between a person's genetic make up and various environmental factors. Although many studies have revealed that several genetic variants increase the risk of cardiovascular disease, the results of these studies remain controversial. The purpose of this study is to identify polymorphisms that confer susceptibility to cardiovascular disease and to clarify the adequacy of reported susceptibility gene polymorphisms. To complete this purpose, we will prospectively study over 5,000 local residents in whom relationship between these polymorphisms and occurrence of cardiovascular disease over 5 years.

Interventions

None listed

Sponsors

Aichi Gakuin University
CollaboratorOTHER
Nagoya University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Healthy subjects who undergo community-based annual health check in Kitanagoya city

Countries

Japan

Contacts

Primary ContactMitsuhiro Yokota, MD, PhD
myokota@dpc.aichi-gakuin.ac.jp+81-52-759-2111
Backup ContactMitsuhiro Yokota, MD, PhD
mitsuhiro.yokota@theranos-inst.com+81-52-744-5515

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026